144 related articles for article (PubMed ID: 25196861)
1. Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer.
Shigeta K; Kosaka T; Yazawa S; Yasumizu Y; Mizuno R; Nagata H; Shinoda K; Morita S; Miyajima A; Kikuchi E; Nakagawa K; Hasegawa S; Oya M
Int J Clin Oncol; 2015 Jun; 20(3):605-12. PubMed ID: 25196861
[TBL] [Abstract][Full Text] [Related]
2. Development of a Nomogram for Predicting Severe Neutropenia Associated With Docetaxel-Based Chemotherapy in Patients With Castration-Resistant Prostate Cancer.
Hirasawa Y; Nakashima J; Sugihara T; Takizawa I; Gondo T; Nakagami Y; Horiguchi Y; Ohno Y; Namiki K; Ohori M; Tachibana M
Clin Genitourin Cancer; 2017 Feb; 15(1):176-181. PubMed ID: 27324052
[TBL] [Abstract][Full Text] [Related]
3. Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
Hamid AA; Willson K; Vincent AD; Tamjid B; Lee M; Bergin A; Gan C; Campbell A; Stewart J; Pezaro C; Tran B; Weickhardt AJ
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e399-e404. PubMed ID: 29318740
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Support Care Cancer; 2014 Dec; 22(12):3219-26. PubMed ID: 24996830
[TBL] [Abstract][Full Text] [Related]
5. Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Enei Y; Atsuta M; Mori K; Obayashi K; Yoshihara K; Kondo Y; Oguchi T; Sadakane I; Habuchi T; Ohyama C; Shariat SF; Egawa S
Prostate; 2022 Oct; 82(14):1322-1330. PubMed ID: 35767376
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer.
Kongsted P; Svane IM; Lindberg H; Sengeløv L
Clin Genitourin Cancer; 2016 Dec; 14(6):e559-e568. PubMed ID: 27102406
[TBL] [Abstract][Full Text] [Related]
8. High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.
Shigeta K; Kosaka T; Kitano S; Yasumizu Y; Miyazaki Y; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Tanoguchi H; Hasegawa S; Oya M
Ann Surg Oncol; 2016 Nov; 23(12):4115-4122. PubMed ID: 27364499
[TBL] [Abstract][Full Text] [Related]
9. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.
Laskey RA; Poniewierski MS; Lopez MA; Hanna RK; Secord AA; Gehrig PA; Lyman GH; Havrilesky LJ
Gynecol Oncol; 2012 Jun; 125(3):625-30. PubMed ID: 22426251
[TBL] [Abstract][Full Text] [Related]
10. Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines.
Wang TY; Chen WM; Yang LY; Chen CY; Chou WC; Chen YY; Chen CC; Lee KD; Lu CH
Support Care Cancer; 2016 Nov; 24(11):4697-703. PubMed ID: 27329415
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel.
Buttigliero C; Tucci M; Vignani F; Di Stefano RF; Leone G; Zichi C; Pignataro D; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Clin Genitourin Cancer; 2018 Aug; 16(4):318-324. PubMed ID: 29866495
[TBL] [Abstract][Full Text] [Related]
12. Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients.
Ozawa K; Minami H; Sato H
Cancer Chemother Pharmacol; 2008 Aug; 62(3):551-7. PubMed ID: 18064462
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for neutropenia after docetaxel-based systemic chemotherapy in Korean patients with castration- resistant prostate cancer.
Kwon WA; Oh TH; Lee JW; Park SC
Asian Pac J Cancer Prev; 2014; 15(8):3443-6. PubMed ID: 24870736
[TBL] [Abstract][Full Text] [Related]
14. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
Hansson EK; Friberg LE
Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
[TBL] [Abstract][Full Text] [Related]
15. Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study.
Maluf FC; de Oliveira FAM; Liedke PER; Brust L; Inocêncio CG; Monteiro FSM; Smaletz O; Cubero DI
Clin Genitourin Cancer; 2021 Jun; 19(3):e171-e177. PubMed ID: 33610484
[TBL] [Abstract][Full Text] [Related]
16. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
17. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Kellokumpu-Lehtinen PL; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H;
Lancet Oncol; 2013 Feb; 14(2):117-24. PubMed ID: 23294853
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.
Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
Med Oncol; 2019 Feb; 36(4):32. PubMed ID: 30815799
[TBL] [Abstract][Full Text] [Related]
19. Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.
Poon DMC; Chan K; Chan TW; Ng B; Siu S; Ng J; Johnson D; Lee KC;
Asia Pac J Clin Oncol; 2021 Apr; 17 Suppl 3():39-47. PubMed ID: 33860642
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
Fukuta F; Kitamura H; Yanase M; Taguchi K; Takahashi A; Kunishima Y; Miyake M; Adachi H; Itoh N; Hirose T; Takagi S; Miyao N; Matsukawa M; Shigyo M; Masumori N
Jpn J Clin Oncol; 2015 Jul; 45(7):682-7. PubMed ID: 25862824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
